FASEB J. Integrated DNA Technologies
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Gu, J.-W.
Right arrow Articles by Tan, W.
PubMed
Right arrow Articles by Gu, J.-W.
Right arrow Articles by Tan, W.
(The FASEB Journal. 2008;22:1164.3.)
© 2008 FASEB


1164.3

Oral Administration of EGCG, an Antioxidant Found in Green Tea, Inhibits Tumor Angiogenesis and Growth of Breast Cancer in Female Mice

Jian-Wei Gu, Emily Young, Jordan Covington, James Wes Johnson and Wei Tan

Physiology & Biophysics, University of Mississippi Medical Center, Jackson, MS

ABSTRACT

Oxidative stress has been implicated in promoting growth and malignancy of cancers including breast cancer. We evaluated whether oral administration of epigallocatechin-3-gallate (EGCG), an antioxidant found in green tea, inhibits vascular endothelial growth factor (VEGF) expression, tumor angiogenesis, and growth of breast cancer in female mice. 7-wk-old female mice (C57BL) were given EGCG 25mg/50ml in drinking water for 5 wks, which was around 50–100 mg/kg/day. The control mice received regular drinking water. In the 2nd wk, ~1x10^5 E0771 (mouse breast cancer) cells were injected in 4th mammary gland of the mice. Tumor size was monitored by measuring tumor cross section area (TCSA). In the end, the tumors were isolated for measuring tumor weight, intratumoral microvessel (IM) density using CD31 immunohistochemistry staining, and VEGF protein levels using ELISA. Oral EGCG treatment caused the significant decreases in TCSA (66%), in tumor weight (68%), in IM density (155±6 vs. 111±20 IM#/mm^2), and in VEGF protein levels (59.0±3.7 vs. 45.7±1.4 pg/mg) of breast tumors, compared to the control, respectively (N = 8; P<0.01). VEGF plasma levels were lower in EGCG mice than control mice (40.8±3.5 vs. 26.5±3.8 pg/ml; P<0.01). The results suggest that antioxidant treatment with EGCG significantly inhibits breast cancer progression via reducing VEGF expression and tumor angiogenesis. (NIH/AA013821 & NIH/HL 51971)





This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Gu, J.-W.
Right arrow Articles by Tan, W.
PubMed
Right arrow Articles by Gu, J.-W.
Right arrow Articles by Tan, W.